Equity Overview
Price & Market Data
Price: $6.61
Daily Change: -$0.46 / 6.96%
Range: $6.12 - $7.27
Market Cap: $1,137,168,256
Volume: 13,188,423
Performance Metrics
1 Week: 11.17%
1 Month: -9.74%
3 Months: -27.66%
6 Months: -34.09%
1 Year: 59.19%
YTD: -17.04%
Company Details
Employees: 952
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.